Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Rosebraugh Commends Ads Addressing Conscientious OTC Use

This article was originally published in The Tan Sheet

Executive Summary

Drug marketers who communicate that their OTC products should be taken with the same care as prescription drugs are sending the right message, according to Curtis Rosebraugh, MD, deputy director of FDA's Office of Nonprescription Products

You may also be interested in...



FDA’s Ganley “Disappointed” By Competitive Pain Reliever Marketing

FDA OTC head Charles Ganley, MD, chastised OTC pain reliever marketers for airing comparative DTC ads in the wake of COX-2 safety concerns during a speech May 6 at the Consumer Healthcare Products Association Regulatory & Scientific Conference in Washington, D.C

Xtreme Tylenol: Wakeboarding, Olympics And Indie Film Festivals

Recent edgy Tylenol promotions, which contrast sharply with previous traditional ads, reflect a dramatic change in marketing that coincides with McNeil Consumer & Specialty Pharmaceuticals' decision to switch ad agencies last year

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel